In this article, we will take a look at the 5 best micro-cap stocks to invest in. You can read our detailed analysis of these and some other micro-cap stocks by going to 10 Best Micro-cap Stocks to Invest In.
5. Zynex, Inc. (NASDAQ:ZYXI)
No of Hedge Funds Holders: 7
Zynex, Inc. (NASDAQ: ZYXI) is a medical technology firm that focuses on the development and distribution of non-invasive medical devices for pain treatment, cardiac monitoring, stroke rehabilitation and neurological diagnostics. This company stands fifth on our list of best micro-cap stocks to invest in.
In the second quarter of 2021 Zynex, Inc. (NASDAQ: ZYXI) reported an EPS of $0.08, beating estimates by $0.01.
On July 16, investment advisory B. Riley upgraded Zynex, Inc. (NASDAQ: ZYXI) stock to Buy from Neutral and increased the price target to $19.5 from $19, appreciating the company’s improved profitability.
Zynex, Inc. (NASDAQ: ZYXI) recorded net revenue of $31.0 million in the second quarter, up 61% from the second quarter of 2020. Similarly, gross margins were 77%, while net income was $2.8 million. The company had $52.9 million in working capital at the end of the second quarter of 2021.
Our data shows that Citadel Investment Group is one the biggest stakeholders of Zynex, Inc. (NASDAQ: ZYXI) with 75,769 shares worth $1.2 million.
At the end of the second quarter of 2021, 7 hedge funds in the database of Insider Monkey held stakes worth $2.8 million in Zynex, Inc. (NASDAQ: ZYXI), down from 6 the preceding quarter worth $8.1 million.
4. SilverBow Resources, Inc. (NYSE:SBOW)
No of Hedge Funds Holders:11
SilverBow Resources, Inc. (NYSE: SBOW) is a leading independent oil and natural gas exploration and production business based in Houston, Texas. This company stands fourth on our list of best micro-cap stocks to invest in.
On September 9, investment advisory Truist upgraded SilverBow Resources, Inc. (NYSE: SBOW) stock to Buy from Hold rating with increase in price target from $30 to $22, appreciating the future growth of the company.
According to Aron chow, lead researcher at Elephant Analytics, with the strength in natural gas prices good cash flow performance is expected by SilverBow Resources, Inc. (NYSE: SBOW). The company is expected to generate positive cash flow of more than $70 million in 2021 and over $80 million in 2022 at current strip.
Our data shows that Strategic Value Partners is one of the biggest stakeholders of SilverBow Resources, Inc. (NYSE: SBOW) with 4.5 million shares worth $103.9 million.
At the end of the second quarter of 2021, 11 hedge funds in the database of Insider Monkey held stakes worth $118.9 million in SilverBow Resources, Inc. (NYSE: SBOW), up from 4 the preceding quarter worth $36.8 million.
3. Cabaletta Bio, Inc. (NASDAQ:CABA)
No of Hedge Funds Holders: 12
Cabaletta Bio, Inc. (NASDAQ: CABA) is a biotechnology firm focused on the development of cellular treatments for autoimmune illnesses. This company stands third on our list of best micro-cap stocks to invest in.
On June 29, investment advisory Mizuho initiated coverage of Cabaletta Bio, Inc. (NASDAQ: CABA) stock with a Buy rating and a price target of $22, stating that it believes that the company would bring transformative innovation into immunology.
On May 3, the results of the first cohort of three patients treated with DSG3-CAART were released by the Cabaletta Bio, Inc. (NASDAQ: CABA), citing that there were no significant side effects.
Our data shows that Adage Capital Management is one of the biggest stakeholders of Cabaletta Bio, Inc. (NASDAQ: CABA) with 3 million shares worth $26.2 million.
At the end of the second quarter of 2021, 12 hedge funds in the database of Insider Monkey held stakes worth $73.1 million in Cabaletta Bio, Inc. (NASDAQ: CABA), up from 11 the preceding quarter worth $91.8 million.
2. Fluidigm Corporation (NASDAQ:FLDM)
No of Hedge Funds Holders: 15
Fluidigm Corporation (NASDAQ: FLDM) is an American public firm that designs, manufactures, and sells biological research equipment using integrated fluidic circuit technology. It stands second on our list of best micro-cap stocks to invest in.
On August 5, a research organization ImaBiotech and Fluidigm Corporation (NASDAQ: FLDM) announced a collaboration and co-marketing agreement for service offerings and product development for Imaging Mass Cytometry, stating that this would play a bigger role in critical clinical and translational research that leads to better health-care decisions.
On Feburary 9, Fluidigm Corporation (NASDAQ: FLDM) announced that a longitudinal study of around 250 pediatric patients infected with the COVID-19 virus will be conducted using Fluidigm mass cytometry technology and the Maxpar Direct Immune Profiling Assay.
Fluidigm Corporation (NASDAQ: FLDM) exclusive CyTOF technology was used in 162 clinical trials by the end of the second quarter 2021. Total revenue for the quarter ending was $31.0 million, up 19% from $26.1 million in the same quarter previous year.
At the end of the second quarter of 2021, 15 hedge funds in the database of Insider Monkey held stakes worth $110.3 million in Fluidigm Corporation (NASDAQ: FLDM), same as the preceding quarter worth $79.7 million.
Our data shows that Indaba Capital Management is one of the biggest stakeholders of Fluidigm Corporation (NASDAQ: FLDM), with 28 million worth $64.8 million.
1. Zogenix, Inc. (NASDAQ:ZGNX)
No of Hedge Funds Holders: 28
Zogenix, Inc. (NASDAQ: ZGNX) is a pharmaceutical firm based in the United States that is dedicated to finding therapeutic treatments with the potential to change the lives of people with rare diseases. Epilepsy and related seizures disorders are the company’s core focus. It is ranked first on our list of best micro-cap stocks to invest in.
On September 9, investment advisory UBS initiated coverage of Zogenix, Inc. (NASDAQ: ZGNX) stock with a Buy rating and a price target of $23, expecting the stock to generate more sales momentum.
On August 26, FINTEPLA oral solution, a product of Zogenix, Inc. (NASDAQ: ZGNX) used for treatment of seizures, was granted Orphan Drug Designation by the Japanese Ministry of Health, Labour, and Welfare. The company considers it a significant step forward in their mission to address the unmet needs of severe, uncommon epilepsy patients all over the world.
Zogenix, Inc. (NASDAQ: ZGNX) earned $18.8 million in sales during Q2 2021, up 37% from $13.7 million in the first quarter. Fintelpa generated $17.5 million in total product sales and $18.8 million in total revenue as reported in Q2 2021. Fintelpa has been prescribed to more than 860 patients till June 30,2021 which is an increase of 22% from the preceding quarters.
Our data shows that RA Capital Management is one of the biggest stakeholders of Zogenix, Inc. (NASDAQ: ZGNX) with 5.3 million shares worth $91.3 million.
At the end of the second quarter of 2021, 28 hedge funds in the database of Insider Monkey held stakes worth $345.7 million in Zogenix, Inc. (NASDAQ: ZGNX) up from 21 the preceding quarter worth $377.4 million.
See also 10 Best Alternative Fuel Stocks to Buy Now and 10 Best Dividend Stocks on Robinhood.
